Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services (WST) delivers essential innovations in pharmaceutical packaging and injectable drug delivery systems. This page provides investors and industry professionals with timely updates on the company’s strategic developments, financial performance, and technological advancements.
Access authoritative reporting on WST’s earnings announcements, regulatory milestones, product launches, and global partnerships. Our curated news ensures you stay informed about critical developments in elastomer-based components, biologics containment, and self-injection device platforms.
Explore updates across key areas: quarterly financial results, manufacturing expansions, compliance achievements, and collaborations with healthcare leaders. Content is rigorously verified to support data-driven decisions while adhering to financial disclosure standards.
Bookmark this page for streamlined access to WST’s evolving role in advancing safe, efficient drug delivery solutions worldwide. Check regularly for unbiased insights into one of pharma packaging’s most innovative players.
West Pharmaceutical Services (WST) has entered an exclusive supply and technology agreement with Corning (GLW) to enhance injectable drug delivery systems. This multimillion-dollar partnership seeks to expand Corning’s Valor® Glass technology, promoting advanced packaging solutions for the pharmaceutical industry aimed at improving patient safety and access to treatments. The collaboration combines West’s NovaPure® components with Corning’s Valor Glass, optimizing manufacturing processes and regulatory navigation for biopharma producers.
West Pharmaceutical Services (WST) announced a $0.18 per share dividend for Q1 2022, payable on February 2, 2022, to shareholders on record by January 19, 2022. Additionally, the company's Board of Directors approved a share repurchase program for 2022, allowing the buyback of up to 650,000 shares. This program aims to enhance shareholder value and is expected to conclude by December 31, 2022, following the expiration of a previous buyback.
West Pharmaceutical Services (NYSE: WST) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 11:15 a.m. EST. The event will be held virtually, allowing investors to access a live audio webcast in the "Investors" section of the company's website. West is a leader in injectable drug solutions, generating over $2.15 billion in sales during fiscal year 2020. With nearly 10,000 employees across 50 sites, West provides over 40 billion components and devices annually.
West Pharmaceutical Services (NYSE: WST) will participate in the Jefferies London Healthcare Conference from November 16-18, 2021, with a Fireside Chat on November 16, 2021, at 5:40 p.m. GMT. The company will also attend the Stephens Investment Conference in Nashville, TN, from December 1-3, 2021, featuring a Fireside Chat on December 3, 2021, at 11:00 a.m. CST. Webcasts for both events will be available on the company's website, with replays accessible for 90 days. West, a leader in injectable solutions, generated over $2.15 billion in sales in FY 2020.
West Pharmaceutical Services reported a strong Q3 2021, with net sales of $706.5 million, a 28.9% increase year-over-year. Reported diluted EPS rose 112% to $2.31. The company raised its full-year net sales guidance to $2.800-$2.810 billion and adjusted diluted EPS guidance to $8.40-$8.50. A quarterly dividend of $0.18 per share was approved, reflecting a 5.9% increase. Sales growth was driven by proprietary products, particularly from the High-Value Product portfolio.
West Pharmaceutical Services announced the launch of its DeltaCube™ Modeling Platform and NovaGuard® SA Pro Safety System for 0.5mL Standard Glass Syringes at Interphex from October 19-21 in New York. The DeltaCube™ platform aids in vial integrity modeling, enhancing decision-making in container closure systems. The NovaGuard® SA Pro system expands product offerings for pre-filled syringes, addressing safety with innovative features to protect against needlestick injuries. This initiative reflects a strategic response to market demands for safer and more efficient drug delivery solutions.
West Pharmaceutical Services (NYSE: WST) will announce third-quarter 2021 financial results on October 28, 2021, before market opening. A conference call will take place at 9:00 a.m. Eastern Time to discuss the results and future business outlook. Interested participants can join by calling 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 5587559. The event will be streamed live on the company's website, with an archived version available afterward until November 4, 2021.
West Pharmaceutical Services (NYSE: WST) has appointed Molly Joseph to its Board of Directors, expanding the board to 11 members. Joseph, 47, previously served as CEO of UnitedHealthcare Group for over a decade, where she led the development of a significant global health business. Her experience includes oversight of extensive medical facilities and strategic corporate development. With her extensive healthcare and board experience, the company anticipates that her expertise will enhance its mission in delivering healthcare solutions worldwide.
West Pharmaceutical Services reported a strong second quarter in 2021, with net sales of $723.6 million, a growth of 37.3%. Organic sales growth was 30.6%, and diluted EPS rose to $2.47, marking a 104% increase. The company raised its full-year 2021 net sales guidance to $2.760-$2.785 billion and adjusted-diluted EPS guidance to $8.05-$8.20. The growth was driven by demand for high-value product components, particularly related to COVID-19 vaccines. Operating cash flow reached $233.1 million, reflecting a 13.6% increase.
FAQ
What is the current stock price of West Pharm Svcs (WST)?
What is the market cap of West Pharm Svcs (WST)?
